Howell Kelli Mari

SEC source: 0001415889-22-008433 · form4-08092022_060817.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, CLINICAL STRATEGIES

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,098

F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · shares: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F2 · balance_after: Includes 2,034 shares acquired under issuer's employee stock purchase plan on May 13, 2022.

SEC source: 0001179110-22-002366 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,114

F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · shares: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

SEC source: 0001179110-22-001694 · edgar.xml · nonDerivative · entry 2

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 547,054

F2 · security: On February 24, 2022, the issuer granted to the reporting person 30,655 RSUs. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date.

F3 · security: Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2 · shares: On February 24, 2022, the issuer granted to the reporting person 30,655 RSUs. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date.

F2 · price: On February 24, 2022, the issuer granted to the reporting person 30,655 RSUs. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date.

F2 · balance_after: On February 24, 2022, the issuer granted to the reporting person 30,655 RSUs. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date.

SEC source: 0001179110-22-001694 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 516,399

F1 · security: On February 24, 2022, the issuer awarded 25,000 restricted stock units (RSUs) to the reporting person upon confirmation by the issuer's compensation committee of satisfaction of certain performance criteria for the fiscal year ended December 31, 2021. The RSUs vest in three equal installments on each of February 24, 2022, February 18, 2023 and February 18, 2024.

F3 · security: Each RSU represents a contingent right to receive one share of the issuer's common stock.

F1 · shares: On February 24, 2022, the issuer awarded 25,000 restricted stock units (RSUs) to the reporting person upon confirmation by the issuer's compensation committee of satisfaction of certain performance criteria for the fiscal year ended December 31, 2021. The RSUs vest in three equal installments on each of February 24, 2022, February 18, 2023 and February 18, 2024.

F1 · price: On February 24, 2022, the issuer awarded 25,000 restricted stock units (RSUs) to the reporting person upon confirmation by the issuer's compensation committee of satisfaction of certain performance criteria for the fiscal year ended December 31, 2021. The RSUs vest in three equal installments on each of February 24, 2022, February 18, 2023 and February 18, 2024.

F1 · balance_after: On February 24, 2022, the issuer awarded 25,000 restricted stock units (RSUs) to the reporting person upon confirmation by the issuer's compensation committee of satisfaction of certain performance criteria for the fiscal year ended December 31, 2021. The RSUs vest in three equal installments on each of February 24, 2022, February 18, 2023 and February 18, 2024.

SEC source: 0001179110-21-008020 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,399

F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · shares: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · balance_after: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

SEC source: 0001179110-21-005569 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,449

F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · shares: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · balance_after: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F2 · balance_after: Includes 2,507 shares acquired under the issuer's employee stock purchase plan on May 14, 2021.

SEC source: 0001179110-21-004763 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 512,467

F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · shares: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

F1 · balance_after: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.

SEC source: 0001179110-21-002082 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523,941

F1 · security: On February 18, 2021, issuer granted to the reporting person 20,000 restricted stock units (RSUs). The RSUs vest in three equal installments on each of the first three anniversaries of the grant date. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F1 · shares: On February 18, 2021, issuer granted to the reporting person 20,000 restricted stock units (RSUs). The RSUs vest in three equal installments on each of the first three anniversaries of the grant date. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F1 · balance_after: On February 18, 2021, issuer granted to the reporting person 20,000 restricted stock units (RSUs). The RSUs vest in three equal installments on each of the first three anniversaries of the grant date. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2 · balance_after: Includes 3,392 shares acquired under the issuer's employee stock purchase plan on May 15, 2020.

SEC source: 0001179110-20-005127 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,549

F1 · date: On April 22, 2020, issuer granted to the reporting person 98,534 restricted stock units (RSUs), subject to receipt of required approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by at least such number as is necessary to vest all of the awards granted on April 22, 2020. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date; provided, however, that the vesting of 50% of these RSUs is subject to the additional condition that the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $7.52 per share during the first three years following the grant date. Should the publicly-traded stock price for the issuer's common stock reach a 30-day average trading price at or above $7.52 per share at any time during such three year period, this pricing condition will be satisfied and will terminate.

F2 · date: Each RSU represents a contingent right to receive one share of the issuer's common stock.

F1 · shares: On April 22, 2020, issuer granted to the reporting person 98,534 restricted stock units (RSUs), subject to receipt of required approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by at least such number as is necessary to vest all of the awards granted on April 22, 2020. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date; provided, however, that the vesting of 50% of these RSUs is subject to the additional condition that the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $7.52 per share during the first three years following the grant date. Should the publicly-traded stock price for the issuer's common stock reach a 30-day average trading price at or above $7.52 per share at any time during such three year period, this pricing condition will be satisfied and will terminate.

F2 · shares: Each RSU represents a contingent right to receive one share of the issuer's common stock.

F1 · balance_after: On April 22, 2020, issuer granted to the reporting person 98,534 restricted stock units (RSUs), subject to receipt of required approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by at least such number as is necessary to vest all of the awards granted on April 22, 2020. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date; provided, however, that the vesting of 50% of these RSUs is subject to the additional condition that the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $7.52 per share during the first three years following the grant date. Should the publicly-traded stock price for the issuer's common stock reach a 30-day average trading price at or above $7.52 per share at any time during such three year period, this pricing condition will be satisfied and will terminate.

F2 · balance_after: Each RSU represents a contingent right to receive one share of the issuer's common stock.

SEC source: 0001179110-20-004796 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402,015

F1 · date: On April 6, 2020, the restricted stock units (RSUs) were granted to the reporting person in connection with the reporting person's election to participate in the issuer's employee salary conversion plan, which was adopted by the Compensation Committee of the issuer's board of directors on April 1, 2020 in response to the novel coronavirus (COVID-19) and the financial impact on the issuer resulting therefrom. Under the terms of the plan, the reporting person is being granted RSUs in lieu of a percentage of the reporting person's cash compensation for the period between April 6, 2020 and July 10, 2020.

F2 · date: Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs vest in full on July 10, 2020.

F1 · shares: On April 6, 2020, the restricted stock units (RSUs) were granted to the reporting person in connection with the reporting person's election to participate in the issuer's employee salary conversion plan, which was adopted by the Compensation Committee of the issuer's board of directors on April 1, 2020 in response to the novel coronavirus (COVID-19) and the financial impact on the issuer resulting therefrom. Under the terms of the plan, the reporting person is being granted RSUs in lieu of a percentage of the reporting person's cash compensation for the period between April 6, 2020 and July 10, 2020.

F2 · shares: Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs vest in full on July 10, 2020.

F3 · price: The conversion price (cash for equity) is based on a 30-day volume weighted average price of the issuer's common stock as of close of market on Friday, April 3, 2020.

F1 · balance_after: On April 6, 2020, the restricted stock units (RSUs) were granted to the reporting person in connection with the reporting person's election to participate in the issuer's employee salary conversion plan, which was adopted by the Compensation Committee of the issuer's board of directors on April 1, 2020 in response to the novel coronavirus (COVID-19) and the financial impact on the issuer resulting therefrom. Under the terms of the plan, the reporting person is being granted RSUs in lieu of a percentage of the reporting person's cash compensation for the period between April 6, 2020 and July 10, 2020.

F2 · balance_after: Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs vest in full on July 10, 2020.

F4 · balance_after: Includes 511 shares acquired under the issuer's employee stock purchase plan on November 15, 2019.

SEC source: 0001179110-19-006124 · edgar.xml · nonDerivative · entry 2

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,368

F2 · date: On May 13, 2019, issuer granted to the reporting person 35,345 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest on the fourth anniversary of grant date; provided, however, that no portion of such restricted stock units shall vest unless the publicly-traded stock price for the issuer's common stock at the close of the market on such fourth anniversary date is equal to or greater than $6.18 per share (representing a 50% increase in the price per share as of the grant date).

F2 · shares: On May 13, 2019, issuer granted to the reporting person 35,345 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest on the fourth anniversary of grant date; provided, however, that no portion of such restricted stock units shall vest unless the publicly-traded stock price for the issuer's common stock at the close of the market on such fourth anniversary date is equal to or greater than $6.18 per share (representing a 50% increase in the price per share as of the grant date).

F3 · shares: Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · balance_after: On May 13, 2019, issuer granted to the reporting person 35,345 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest on the fourth anniversary of grant date; provided, however, that no portion of such restricted stock units shall vest unless the publicly-traded stock price for the issuer's common stock at the close of the market on such fourth anniversary date is equal to or greater than $6.18 per share (representing a 50% increase in the price per share as of the grant date).

F3 · balance_after: Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F4 · balance_after: Includes 8,004 shares acquired under the issuer's employee stock purchase plan on May 15, 2019.

SEC source: 0001179110-19-006124 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,019

F1 · date: On May 13, 2019, issuer granted to the reporting person 141,379 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date; provided, however, that no portion of the restricted stock units shall vest at any time during the first four years following the grant date unless and until the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $5.36 per share (representing a 30% increase in the price per share as of the grant date). Should the publicly traded stock price for the issuer's common stock reach a 30-day average trading price at or above $5.36 per share, this pricing condition on the vesting of the restricted stock units shall be satisfied, and shall terminate.

F1 · shares: On May 13, 2019, issuer granted to the reporting person 141,379 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date; provided, however, that no portion of the restricted stock units shall vest at any time during the first four years following the grant date unless and until the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $5.36 per share (representing a 30% increase in the price per share as of the grant date). Should the publicly traded stock price for the issuer's common stock reach a 30-day average trading price at or above $5.36 per share, this pricing condition on the vesting of the restricted stock units shall be satisfied, and shall terminate.

F3 · shares: Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F1 · balance_after: On May 13, 2019, issuer granted to the reporting person 141,379 restricted stock units, subject to stockholder approval of an amendment to issuer's 2016 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 4,000,000 shares. The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date; provided, however, that no portion of the restricted stock units shall vest at any time during the first four years following the grant date unless and until the publicly-traded stock price for the issuer's common stock reaches a 30-day average trading price equal to or above $5.36 per share (representing a 30% increase in the price per share as of the grant date). Should the publicly traded stock price for the issuer's common stock reach a 30-day average trading price at or above $5.36 per share, this pricing condition on the vesting of the restricted stock units shall be satisfied, and shall terminate.

F3 · balance_after: Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

SEC source: 0001179110-19-003774 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,640

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · balance_after: Includes 6,830 shares acquired under the issuer's employee stock purchase plan on November 15, 2018.

SEC source: 0001179110-18-010076 · edgar.xml · derivative · entry 2

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,006

Underlying: Common Stock · 71,006 shares

Expires 2028-07-30

F3 · derivative.exercise_date: The option will vest 25% on the first anniversary of the grant date and thereafter in 36 equal monthly installments; provided, however, that no portion of the option shall be exercisable at any time during the first four years following the grant date unless and until the publicly-traded stock price for the securities underlying the option reaches a 30-day average trading price equal to or above $4.20 per share. Should the publicly-traded stock price for the securities underlying the option reach a 30-day average trading price at or above $4.20 per share, this pricing condition on the exercise of the option shall be satisfied, and shall terminate.

SEC source: 0001179110-18-010076 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,810

F1 · date: On July 30, 2018, issuer granted to the reporting person 48,810 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · date: The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date.

F1 · shares: On July 30, 2018, issuer granted to the reporting person 48,810 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · shares: The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date.

F1 · balance_after: On July 30, 2018, issuer granted to the reporting person 48,810 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · balance_after: The restricted stock units vest in four equal installments on each of the first four anniversaries of the grant date.

SEC source: 0001179110-18-004318 · edgar.xml · derivative · entry 2

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-03-11

F3 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and thereafter in 36 equal monthly installments.

SEC source: 0001179110-18-004318 · edgar.xml · nonDerivative · entry 1

Howell Kelli Mari · CIK 0001734485 · EVP, Clinical Strategies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · security: On March 12, 2018, issuer granted to the reporting person 50,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · security: The restricted stock units vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date.

F1 · shares: On March 12, 2018, issuer granted to the reporting person 50,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · shares: The restricted stock units vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date.

F1 · balance_after: On March 12, 2018, issuer granted to the reporting person 50,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

F2 · balance_after: The restricted stock units vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date.